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HIV-associated cryptococcal meningitis continues to pose a major clinical challenge. Mortality rates 
of 20-40% have been reported in recent clinical trials using currently recommended amphotericin-
based treatments[1, 2], and the clinical course of illness in those who do survive is frequently 
complicated by prolonged or recurrent disease[3, 4]. Immune reconstitution inflammatory syndrome 
(IRIS) occurs in 15-20% of individuals who survive their initial illness and initiate antiretroviral 
therapy (ART), causing a further substantial burden of morbidity and mortality[3-6]. Determining the 
underlying immune pathology of IRIS, with a view to developing effective prevention or treatment 
and enabling safe and rapid initiation of ART is, therefore, of considerable importance, and a core 
component of improving patient outcomes from this severe opportunistic infection. 
 
The development of cryptococcal IRIS (C-IRIS) is strongly associated with a poor baseline 
inflammatory response, an accompanying high organism or antigen load, and rapid immune 
reconstitution from a low baseline CD4
+
 cell count on ART[3, 7-9].  Although the specific host and 
pathogen attributes leading to the paucity of effective immune responses and defective antigen 
clearance during the initial cryptococcal meningitis episode are unknown,  human studies suggest that 
persistently elevated cryptococcal antigen levels despite antifungal therapy leads to increased pro-
inflammatory signalling from antigen-presenting cells, with a lack of effective antigen clearance due 
to the absence of adequate T-cell help[10-14]. Development of cryptococcal IRIS has been strongly 
associated with high CNS expression of the chemokines MCP-1(CCL2) and MIP-1α(CCL3) at initial 
CM presentation and at ART initiation[12, 13] which, following immune restoration with ART, is 
hypothesized to result in an influx of inflammatory cells into the CNS, excessive dysregulated local 
inflammation, and IRIS[11-13, 15, 16].  
 
 
In this issue of the Journal of Infectious Diseases, Yoon et al. report a novel association between 
plasma antibody responses at the time of ART initiation and the development of C-IRIS in a well 
characterised patient cohort from South Africa[17]. Lower levels of plasma IgM antibodies to the 
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cryptococcal polysaccharide antigen glucuronoxylomannan (GXM), laminarin (Lam) – -(1.3)-
glucan containing polysaccharide, and pustulan – -(1.6)-glucan, and total plasma IgM, were 
associated with higher risk C-IRIS. Given our lack of detailed understanding of C-IRIS 
immunopathology, and the focus of most C-IRIS research to date on macrophage / monocyte[8, 16, 
18, 19] and T-cell mediated immunity[5, 12, 13, 20], these findings offer potentially important new 
insights into the mechanisms of disease and offer interesting avenues for future research. The role of 
antibody-mediated protection in HIV-related cryptococcal infection remains uncertain[21, 22] and, as 
Yoon and colleagues discuss in their article, although animal model and in vitro studies[23-27], along 
with some human data[28-30], support a role for natural antibody immunity in the host defense 
against cryptococcal infection, the mechanisms involved remain unclear. 
 
The observation that less robust IgM antibody responses to fungal antigens at the time of ART 
initiation were associated with higher likelihood of subsequent C-IRIS may indicate an important role 
for antibody-mediated protection during cryptococcal meningitis, and fit with the overarching 
hypothesis that a poor initial immune response and subsequent failure of effective immune clearance 
of cryptococcal antigens are key predisposing factors for IRIS. Such attributions of causality must be 
made with caution, however. The South African patient cohort from which the samples were derived 
is one of the largest and best characterized to date[3], but remains a relatively small sample. Few data 
were available regarding baseline characteristics of patients prior to antifungal therapy. And 
adjustments, which are difficult for multiple factors in a small study, were not made for some of the 
known predictors of C-IRIS, including CSF cytokine and chemokine levels. Prior studies performing 
detailed immune-phenotyping in HIV-associated cryptococcal meningitis have demonstrated the 
complex interplay between innate and adaptive immune response and the close correlation of many of 
the soluble and cellular immune markers measured[13, 18-20], making interpretation of potential 
mechanisms of protection problematic. The correlation seen in the current study between IgM levels 
and CD4
+
 cell counts, known to play a critical role in C-IRIS pathogenesis[15], highlights the 
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difficulty of untangling the relative contributions of interconnected elements of the effective host 
immune response, even given  the adjustment made for CD4 cell counts in the study. 
 
The findings of Yoon and colleagues provide further impetus for larger prospective studies to better 
determine the role of the host immune response in HIV-related cryptococcal infection,  both to 
understand causal pathways to C-IRIS and, also, the immune correlates of outcome more generally. 
These studies should include detailed clinical and microbiological characterization of cases with 
longitudinal follow-up, sample collection for immune phenotyping, including antibody responses and, 
ideally, genotyping, with the ultimate aim of identifying pathways amenable to intervention to reduce 
the high rates of morbidity and mortality due to cryptococcal meningitis worldwide[31]. Pending 
these studies, efforts should be focused on reducing the incidence of C-IRIS through the use of 
rapidly fungicidal antifungal drug combinations[1, 2] and appropriately timed ART initiation[32, 33] 
based on evidence from randomized controlled trials, and ensuring clinicians recognize C-IRIS early 
and manage cases appropriately. Data from our recent trials suggest that with these steps in place the 
morbidity related to C-IRIS can be reduced substantially in patients initiating ART following 
cryptococcal meningitis[1, 4, 34], and C-IRIS should no longer carry the devastating prognosis that 
has historically been associated with the condition. 
Footnotes: Dr. Jarvis reports grants from Gilead Sciences Europe outside of the submitted work. Dr. 
Harrison reports grants from Gilead Sciences, personal fees from Viamet, Pfizer, and Gilead Sciences 
outside of the submitted work. 
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